Literature DB >> 21917890

Altered expression of SHIP, a Toll-like receptor pathway inhibitor, is associated with the severity of liver fibrosis in chronic hepatitis C virus infection.

Antonios Katsounas1, Martin Trippler, Shyam Kottilil, Richard A Lempicki, Guido Gerken, Joerg F Schlaak.   

Abstract

Hepatitis C-related fibrogenesis has been shown to involve complex interactions between peripheral and hepatic immune responses. Peripheral whole blood (PB) samples from patients with chronic hepatitis C (n = 36) were subjected to microarray analysis in order to identify gene expression patterns associated with immune pathways in PB and hepatic fibrosis. Distinct regulation of gene expression of inositol polyphosphate-5-phosphatase/145kDa (INPP5D or SHIP), a TLR2/TLR4-inhibitor, and heat shock protein 8/22 kDa (HSPB8), an endogenous TLR4-ligand, during fibrogenesis was identified and could be confirmed by quantitative reverse-transcription polymerase chain reaction. These results suggest a potential link between peripheral activity of the TLR4-pathway, peripheral SHIP-dependent immune regulation, and liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917890      PMCID: PMC3173502          DOI: 10.1093/infdis/jir500

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  LPS-induced upregulation of SHIP is essential for endotoxin tolerance.

Authors:  Laura M Sly; Michael J Rauh; Janet Kalesnikoff; Christine H Song; Gerald Krystal
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

2.  Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus.

Authors:  Timothy L Mosbruger; Priya Duggal; James J Goedert; Gregory D Kirk; W Keith Hoots; Leslie H Tobler; Michael Busch; Marion G Peters; Hugo R Rosen; David L Thomas; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

Review 3.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms.

Authors:  Jinzhong Qin; Youcun Qian; Jianhong Yao; Cui Grace; Xiaoxia Li
Journal:  J Biol Chem       Date:  2005-05-02       Impact factor: 5.157

5.  Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis.

Authors:  Mieke F Roelofs; Wilbert C Boelens; Leo A B Joosten; Shahla Abdollahi-Roodsaz; Jeroen Geurts; Liza U Wunderink; B Willem Schreurs; Wim B van den Berg; Timothy R D J Radstake
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

6.  SHIP represses the generation of alternatively activated macrophages.

Authors:  Michael J Rauh; Victor Ho; Carla Pereira; Anita Sham; Laura M Sly; Vivian Lam; Lynsey Huxham; Andrew I Minchinton; Alice Mui; Gerald Krystal
Journal:  Immunity       Date:  2005-10       Impact factor: 31.745

7.  Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Motonari Takashima; Yasuhiro Kuramitsu; Yuuichiro Yokoyama; Norio Iizuka; Toshifusa Toda; Isao Sakaida; Kiwamu Okita; Masaaki Oka; Kazuyuki Nakamura
Journal:  Proteomics       Date:  2003-12       Impact factor: 3.984

8.  Chronic hepatitis. An update on terminology and reporting.

Authors:  K P Batts; J Ludwig
Journal:  Am J Surg Pathol       Date:  1995-12       Impact factor: 6.394

Review 9.  Endotoxin tolerance: is there a clinical relevance?

Authors:  Jean-Marc Cavaillon; Christophe Adrie; Catherine Fitting; Minou Adib-Conquy
Journal:  J Endotoxin Res       Date:  2003

10.  Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein.

Authors:  Yook-Wah Choi; Yee-Joo Tan; Seng Gee Lim; Wanjin Hong; Phuay-Yee Goh
Journal:  Biochem Biophys Res Commun       Date:  2004-05-28       Impact factor: 3.575

View more
  3 in total

1.  AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.

Authors:  Jennifer Cross; Grant R Stenton; Curtis Harwig; Csaba Szabo; Tiziana Genovese; Rosanna Di Paola; Emanuale Esposito; Salvatore Cuzzocrea; Lloyd F Mackenzie
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 2.  Intensive Care Therapy for Patients with Advanced Liver Diseases.

Authors:  Antonios Katsounas; Ali Canbay
Journal:  Visc Med       Date:  2018-08-08

3.  DHFR silence alleviated the development of liver fibrosis by affecting the crosstalk between hepatic stellate cells and macrophages.

Authors:  Yu Peng; Zedong Li; Sheng Chen; Jun Zhou
Journal:  J Cell Mol Med       Date:  2021-10-09       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.